유리체강내 트리암시놀론 주입술 후 예방적 안압하강제의 효과

다국어 초록 (Multilingual Abstract)

Purpose: The purpose of this study was to investigate the prophylactic effect of brimonidine 0.15% on intraocular pressure (IOP) elevation and the risk factors for its elevation after intravitreal triamcinolone acetonide injection (IVTA). Methods: A prospective, randomized clinical trial was conducted on 67 eyes of 64 patients undergoing IVTA. Eyes were randomly divided into two groups, those which had used brimonidine 0.15% (40 eyes) and those which had not used it (27 eyes). IOP was measured preoperatively, at one week, and monthly until six months post-injection in each group. Results: The mean post‐injection IOP at one week was 11.93±3.36 mmHg for the group that had used brimonidine and 13.58±3.25 mmHg for the group that had not used it. The difference between the two groups was statistically significant at one week (p=0.049), but others were not statistically significant. An elevation in the IOP of more than 22 mmHg was seen in 8 eyes (20%) in the group using brimonidine and in 7 eyes (25.9%) in the group not using brimonidine. There was no difference in the incidence of IOP elevation between the two groups. Conclusions: Prophylactic use of brimonidine 0.15% will prevent sudden IOP elevation and will, therefore, prevent damage to the retina and optic nerve. However, in the long term, there is no prophylactic effect of brimonidine 0.15% on IOP elevation because there was no difference in the incidence of IOP elevation of more than 22 mmHg between the two groups.

참고문헌 (Reference)

1 양연희, "유리체내 트리암시놀론 주사 후 안압의 변화" 대한안과학회 45 (45): 1081-1085, 2004

2 Dwinger MC, "Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection" 222 : 638-642, 2005

3 Kubota T, "Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide" 15 : 117-119, 2006

4 Katz LJ, "Twelve‐month evaluation of brimonidine purite versus brimonidine in patients with glaucoma or ocular hypertension" 11 : 119-126, 2002

5 Barnebey HS, "The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty" 100 : 1083-1088, 1993

6 Shields MB, "Textbook of glaucoma" Williams & Wilkins 323-, 1998

7 Lee EW, "Short‐term intraocular pressure trends after intravitreal triamcinolone injection" 143 : 365-367, 2007

8 Lee EW, "Short‐term intraocular pressure trends after intravitreal triamcinolone injection" 143 : 365-367, 2007

9 Benz MS, "Short‐term course of intraocular pressure after intravitreal injection of triamcinolone acetonide" 113 : 1174-1178, 2006

10 Bigger JF, "Sensitivity to glucocorticoids in primary open angle glaucoma" 287 : 992-, 1972

11 Jonas JB, "Secondary chronic openangle glaucoma after intravitreal triamcinolone acetonide" 121 : 729-730, 2003

12 Wheeler LA, "Role of alpha‐2 adrenergic receptors in neuroprotection and glaucoma" 45 : 290-294, 2001

13 Wheeler L, "Role of alpha-2 agonists in neuroprotection" 48 : 47-51, 2003

14 Antcliff RJ, "Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study" 108 : 765-772, 2001

15 Danis RP, "Intravitreal triamcinolone acetonide in exudative age‐relative macular degeneration" 20 : 244-250, 2000

16 Smithen LM, "Intravitreal triamcinolone acetonide and intraocular pressure" 138 : 740-743, 2004

17 Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy" 84 : 1064-1067, 2000

18 Jonas JB, "Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy" 131 : 468-471, 2001

19 Park HY, "Intraocular pressure elevation after intravitreal triamcinolone acetonide injection" 19 : 122-127, 2005

20 Becker B, "Intraocular pressure and its response to topical corticosteroids in diabetes" 76 : 477-483, 1966

21 Jonas JB, "Intraocular pressure after intravitreal injection of triamcinolone acetonide" 87 : 24-27, 2003

22 Beer PM, "Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single injection" 110 : 681-686, 2003

23 Jonas JB, "Intraocular availability of triamcinolone acetonide after intravitreal injection" 137 : 560-562, 2004

24 Seong HK, "Immediate natural course of IOP after IVTA and the effect of preoperative ocular massage" 48 : 808-814, 2007

25 Becker B, "Glaucoma and corticosteroid provocative testing" 74 : 621-624, 1965

26 Machemer R, "Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye" 16 : 166-167, 1996

27 Kotliar K, "Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model" 85 : 777-781, 2007

28 Seong GJ, "Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy" 31 : 308-314, 2000

29 Singh IP, "Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection" 138 : 286-287, 2004

30 Scholes GN, "Clearance of triamcinolone from vitreous" 103 : 1567-1569, 1985

31 Kim TH, "Change of residual period and clearance rate of intravitreal triamcinolone according to initial dosage" 46 : 1569-1574, 2005

32 Lai RK, "Alpha‐2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat" 19 : 175-185, 2002